Literature DB >> 8274460

Histamine stimulates normal human melanocytes in vitro: one of the possible inducers of hyperpigmentation in urticaria pigmentosa.

Y Tomita1, K Maeda, H Tagami.   

Abstract

Isolated normal human melanocytes became enlarged and more dendritic in association with an increase in the activity of tyrosinase and the amount of b-locus protein when they were cultured with 0.1-10 microM histamine in vitro. However, histamine did not exert a proliferative effect on them. The stimulatory effect of histamine was observable even 6 h after starting the treatment. This stimulation seems not to be pharmacologically mediated through histamine receptors, because it was inhibited neither by pyrilamine, a histamine H-1 antagonist, nor by cimetidine, a H-2 antagonist. Imidazole derivatives that are rapidly metabolized from histamine in vivo and in vitro also stimulated the melanocytes. We propose that high concentrations of histamine and its imidazole metabolites continuously produced in the lesions of urticaria pigmentosa are probable causative factors of its characteristic skin pigmentation.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8274460     DOI: 10.1016/0923-1811(93)90005-a

Source DB:  PubMed          Journal:  J Dermatol Sci        ISSN: 0923-1811            Impact factor:   4.563


  3 in total

1.  Urticaria Pigmentosa Mimicking Multiple Lentigine-like Brownish Macules in a 22-Month-Old Boy.

Authors:  Joon Hyuk Suh; Kui Young Park; Seong Jun Seo
Journal:  J Korean Med Sci       Date:  2017-06       Impact factor: 2.153

2.  Cutaneous mastocytosis combined with eruptive melanocytic nevi and melanoma. Coincidence or a linkage in the pathogenesis?

Authors:  Pietro Donati; Giovanni Paolino; Michele Donati; Chiara Panetta
Journal:  J Dermatol Case Rep       Date:  2014-09-30

Review 3.  Timeline of the Development of Skin-Lightening Active Ingredients in Japan.

Authors:  Kazuhisa Maeda
Journal:  Molecules       Date:  2022-07-26       Impact factor: 4.927

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.